ALIVE Israel Healthtech Fund

Navina is a technology company that has developed an AI-driven platform aimed at transforming disorganized patient data into clear and actionable patient portraits. This innovative approach allows physicians to quickly assess complex cases, significantly enhancing the diagnostic process and patient care. By utilizing artificial intelligence and machine learning, Navina's platform organizes essential patient information in a way that is intuitively accessible, ensuring that critical data is easily understood and contextually relevant. This capability not only improves patient wellness but also supports better financial outcomes for healthcare providers and payers. Additionally, Navina collaborates with the American Academy of Family Physicians Innovation Lab, further solidifying its commitment to advancing healthcare through technology.

Magenta Medical Ltd. is a privately held company based in Kadima, Israel, founded in 2012. The company specializes in developing innovative medical devices aimed at treating acute decompensated heart failure. Its flagship product is a temporary venous catheter-based therapy that includes a self-expanding heart pump. This device targets critical issues related to acute heart failure, particularly renal venous congestion, which adversely affects both cardiac and renal function. By enabling physicians to more effectively manage fluid and salt removal in patients, Magenta Medical's technology enhances patient safety and supports kidney function, offering a promising solution for better management of heart failure.

Vessi Medical is an Israeli medical device startup focused on innovating treatment for Non-Muscle-Invasive Bladder Cancer (NMIBC) through a novel surface cryotherapy approach. This method employs extreme cold to freeze and eliminate abnormal tissue, addressing the limitations of traditional first-line therapies like TransUrethral Resection of Bladder Tumor (TURBT), which can be invasive, costly, and often result in cancer recurrence. Vessi's technology offers a minimally invasive, office-based therapy that reduces the need for hospital stays and repeat surgeries, which are common in conventional treatments. The system comprises a standalone console and a disposable catheter that allows for targeted cell destruction while safeguarding healthy bladder tissue. Vessi Medical, supported by the Trendlines Group and led by experienced professionals in the medical device and cryotherapy fields, has already shown promising results in animal studies. The company's initial focus is on the $1.2 billion NMIBC market, with plans to expand into treatment options for overactive bladder and urinary tract infections in the future.

Gina Life is femtech company developing a platform of biomarkers strategy supported by AI for early detection in women’s health space.

Append Medical is focused on developing a next-generation transcatheter Left Atrial Appendage (LAA) closure system, aimed at preventing strokes by mitigating the risk of blood clot leakage to the brain. Currently in the pre-clinical in-vivo trial phase, the company's innovative approach involves tissue invagination and closure by suture, rather than traditional implants. This method is designed to simplify the treatment of atrial fibrillation while minimizing the presence of foreign materials at the closure site, thereby reducing the risk of device-related thromboembolism. The LAA closure market is anticipated to grow significantly, with estimates suggesting it could reach $25 billion in the coming years. Append Medical is also a participant in MEDX Xelerator, a medtech incubator supported by various industry leaders.

Magenta Medical Ltd. is a privately held company based in Kadima, Israel, founded in 2012. The company specializes in developing innovative medical devices aimed at treating acute decompensated heart failure. Its flagship product is a temporary venous catheter-based therapy that includes a self-expanding heart pump. This device targets critical issues related to acute heart failure, particularly renal venous congestion, which adversely affects both cardiac and renal function. By enabling physicians to more effectively manage fluid and salt removal in patients, Magenta Medical's technology enhances patient safety and supports kidney function, offering a promising solution for better management of heart failure.

Thesis offers personalized brain supplements that cater to all types of brains. They create potent nutritional compounds to improve mental function and provide individualized suggestions depending on their customers' goals and brain chemistry.

Mediscope is an innovative platform focused on addressing the challenges of social isolation and its detrimental effects on mental and physical health. By leveraging evidence-based peer support and benefits navigation, Mediscope aims to enhance health outcomes and reduce medical costs. The platform facilitates meaningful connections among users, allowing them to share experiences and gain insights from individuals who have faced similar challenges. Through its AI-powered features, Mediscope empowers individuals to navigate their health journeys more effectively, promoting engagement and community support to combat loneliness and foster well-being.

Navina is a technology company that has developed an AI-driven platform aimed at transforming disorganized patient data into clear and actionable patient portraits. This innovative approach allows physicians to quickly assess complex cases, significantly enhancing the diagnostic process and patient care. By utilizing artificial intelligence and machine learning, Navina's platform organizes essential patient information in a way that is intuitively accessible, ensuring that critical data is easily understood and contextually relevant. This capability not only improves patient wellness but also supports better financial outcomes for healthcare providers and payers. Additionally, Navina collaborates with the American Academy of Family Physicians Innovation Lab, further solidifying its commitment to advancing healthcare through technology.

OncoHost is a clinical-stage biotechnology company focused on enhancing cancer therapy outcomes through personalized strategies. Founded in 2017 and headquartered in Binyamina, Israel, the company employs proprietary proteomic analysis to evaluate individual patient responses to treatments, addressing the critical challenge of therapy resistance in oncology. By analyzing proteomic changes in blood samples, OncoHost’s platform facilitates the early identification of non-responsiveness to cancer therapies and aids in discovering new drug targets. The integration of bioinformatics, systems biology, and machine learning allows OncoHost to predict clinical benefits from specific therapies, which can guide healthcare providers in tailoring treatment plans. Collaborating with leading academic and clinical partners, OncoHost is advancing its clinical programs to improve patient outcomes through personalized diagnostics and therapeutic strategies.

Beyeonics specializes in advanced surgical visualization technologies, aiming to enhance the information available to surgeons during procedures. Established in 2012 by a team of experienced engineers, the company is based in Israel and is developing innovative platforms that utilize augmented and virtual reality to replace traditional surgical microscopes. This technology allows for the real-time integration of vast amounts of data, which significantly improves surgical efficiency and patient safety. Beyeonics is focused on expanding its offerings to various surgical applications, including spine surgery, minimally invasive procedures, robotic surgery, and cardiovascular catheterization. The company collaborates with notable medical professionals, including those from the Tel Aviv Sourasky Medical Center and Retinal Consultants of Arizona, to ensure that its solutions meet the evolving needs of the medical community.

Innovalve is an early-stage medical device company founded in 2017 and based in Israel. The company specializes in the development of catheter-based heart valve therapies aimed at treating cardiovascular diseases. Innovalve's primary innovation is an artificial mitral valve that can be replaced using a minimally invasive catheter. This technology provides healthcare professionals with an alternative method for treating patients with heart conditions, enhancing the options available for heart surgery and improving patient care.